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Abstract
Background: Epigenetic regulation is important in hematopoiesis, but the involvement of histone variants is poorly
understood. Myelodysplastic syndromes (MDS) are heterogeneous clonal hematopoietic stem cell (HSC) disorders
characterized by ineffective hematopoiesis. MacroH2A1.1 is a histone H2A variant that negatively correlates with the
self-renewal capacity of embryonic, adult, and cancer stem cells. MacroH2A1.1 is a target of the frequent U2AF1
S34F mutation in MDS. The role of macroH2A1.1 in hematopoiesis is unclear.
Results: MacroH2A1.1 mRNA levels are significantly decreased in patients with low-risk MDS presenting with
chromosomal 5q deletion and myeloid cytopenias and tend to be decreased in MDS patients carrying the U2AF1
S34F mutation. Using an innovative mouse allele lacking the macroH2A1.1 alternatively spliced exon, we
investigated whether macroH2A1.1 regulates HSC homeostasis and differentiation. The lack of macroH2A1.1
decreased while macroH2A1.1 haploinsufficiency increased HSC frequency upon irradiation. Moreover, bone
marrow transplantation experiments showed that both deficiency and haploinsufficiency of macroH2A1.1 resulted
in enhanced HSC differentiation along the myeloid lineage. Finally, RNA-sequencing analysis implicated
macroH2A1.1-mediated regulation of ribosomal gene expression in HSC homeostasis.
Conclusions: Together, our findings suggest a new epigenetic process contributing to hematopoiesis regulation.
By combining clinical data with a discrete mutant mouse model and in vitro studies of human and mouse cells, we
identify macroH2A1.1 as a key player in the cellular and molecular features of MDS. These data justify the
exploration of macroH2A1.1 and associated proteins as therapeutic targets in hematological malignancies.
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Background
The healthy hematopoietic stem cell (HSC) pool is
maintained by genetically and epigenetically regulated
gene expression [1, 2]. When these systems go awry, ab-
errant hematopoietic stem and progenitor cells may
emerge (reviewed in [3]), which are implicated in the de-
velopment of a heterogeneous group of disorders called
myelodysplastic syndromes (MDS). MDS are character-
ized by ineffective hematopoiesis, leading to variable per-
ipheral blood cytopenias and risk of transformation to
acute myeloid leukemia (AML) [4]. MDS can remain
stable for many years with few symptoms or can rapidly
progress into a more aggressive MDS subtype [5];
current treatment options, however, are limited and
often ineffective. Studies have started to identify com-
mon mutations underlying HSC dysregulation in MDS,
but more progress is needed to identify the molecules
and pathways contributing to disease mechanisms.
Recent data have suggested a possible role for histone
variants, in particular, the macroH2A1 splice variant
macroH2A1.1, in the pathological processes underlying
MDS development [6]. Histone macroH2A1 exists as two
mutually exclusive exon-spliced isoforms: macroH2A1.1
and macroH2A1.2. These isoforms display largely divergent
functions in cell differentiation and tumorigenesis [7, 8].
MacroH2A1.1 is a potent transcriptional modulator associ-
ated with favorable outcomes in several solid tumor types,
restriction of cancer stem-cell emergence, and PARP1 (Poly
(ADP-ribose) Polymerase-1)-dependent chromatin remod-
eling [8–20]. The gene encoding human macroH2A1.1 and
macroH2A1.2, H2AFY, is found on the long arm of
chromosome 5 (at 5q31.1), which is deleted in ~ 20% of
MDS patients. Between 45 and 85% of MDS patients ex-
hibit mutations in various components of the RNA spliceo-
some machinery, including U2AF1, ZRSR2, SRSF2, and
SF3B1 [21]. Recapitulation of the common U2AF1 S34F
mutation in mice reproduces aspects of human MDS and
induces dysregulated splicing of multiple gene products, in-
cluding H2AFY [22]. Yip et al. recently demonstrated that
bone marrow (BM) progenitor cells from MDS patients
with an endogenous U2AF1 S34F mutation showed aber-
rantly spliced H2AFY, resulting in reduced macroH2A1.1,
but not macroH2A1.2, isoform expression in both erythroid
and granulomonocytic derived colonies [6]. shRNA-medi-
ated silencing of macroH2A1.1 in BM progenitor cells led
to increased apoptosis and decreased differentiation when
cells were cultured under erythroid and granulomonocytic
conditions [6].
Here, we report for the first time that loss of
macroH2A1.1 expression in mice led to the dysregulation
of myeloid differentiation. RNA-sequencing identified de-
fective production of ribosomal mRNAs as a potential
mechanism for disrupted HSC homeostasis following
macroH2A1.1 depletion. Thus, macroH2A1.1 delineates
its function in HSC homeostasis and differentiation in
mice. Moreover, we found that macroH2A1 isoforms’
mRNA levels are significantly decreased in MDS patients
with a 5q deletion compared to other MDS groups and
healthy individuals.
Results
Mice lacking macroH2A1.1 exhibit blood abnormalities
under a steady state
As macroH2A1.1 expression is decreased in U2AF1 S34F
MDS patients and its knockdown in vitro perturbs eryth-
roid and granulomonocytic differentiation [6], we sought
to investigate macroH2A1.1 function in mice using a gene
KO approach. We first generated a mouse line carrying a
conditional macroH2A1 allele that permits selective elim-
ination of one of the two macroH2A protein isoforms
using either Cre or Dre recombinase (Fig. 1a).
Mice carrying the targeted (floxed; fl) allele exhibited
no phenotype compared to wild-type (WT) mice and
were viable and fertile (data not shown). When crossed
to deleter HPRT-Cre mice (129S1/Sv-Hprttm1(CAG--
cre)Mnn/J) that ubiquitously express Cre in early develop-
ment [23], the loxP-flanked cassette and exon 6b were
removed thereby generating macroH2A1.1fl/− mice.
These mice were then intercrossed to generate
macroH2A1.1−/− (KO) mice. MacroH2A1.1fl/− and
macroH2A1.1−/− mice were morphologically and histo-
logically indistinguishable from their WT and macro-
H2A1.1fl/fl littermates under normal conditions, with no
overt metabolic, reproductive, or behavioral abnormal-
ities. To confirm the absence of macroH2A1.1 in the
KO cells, we isolated murine embryonic fibroblasts
(MEFs) from macroH2A1.1fl/fl and macroH2A1.1−/−
mice, which exhibited comparable cell morphology
(Fig. 1b, left panel), and analyzed extracted protein ly-
sates by Western blotting. MacroH2A1.1, but not
macroH2A1.2, protein expression was abolished in
macroH2A1.1−/− KO MEFs (Fig. 1b). We then confirmed
undetectable macroH2A1.1 mRNA levels in a panel of tis-
sues isolated from adult (3-month-old) macroH2A1.1−/−
mice, compared to macroH2A1.1fl/fl littermates, and reduced
macroH2A1.1 mRNA levels by 50% in macroH2A1.1fl/− het-
erozygous (HET) mice (Fig. 1c). MacroH2A1.2 transcript
abundance was comparable between all macroH2A1.1 geno-
types (Fig. 1c). These results confirmed efficient Cre-medi-
ated macroH2A1.1 allele targeting.
Blood counts and biochemical tests identified a low
hematocrit and reduced neutrophil counts in macro-
H2A1.1fl/− HET and macroH2A1.1−/− KO mice com-
pared to macroH2A1.1fl/fl and WT littermates; an
opposite trend was observed for lymphocyte and eosino-
phil cell counts (Additional file 1: Figure S2A and B). No
difference in cholesterol or triglyceride levels was ob-
served between groups, but decreased liver transaminase
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levels were observed in macroH2A1.1fl/− HET and
macroH2A1.1−/− KO mice (Additional file 1: Figure
S2C). The blood count abnormalities are reminiscent of
those observed in human patients with MDS. We also
detected lower alanine transaminase (ALT) and aspar-
tate transaminase (AST) levels in macroH2A1.1fl/−
HET, and to a greater extent in macroH2A1.1−/− KO
mice (Additional file 1: Figure S2C), which in humans
is associated with higher all-cause mortality [24, 25].
MacroH2A1.1 haploinsufficiency or deficiency perturbs
hematopoiesis following DNA damage
An expansion of phenotypically primitive HSCs is often
observed in patients with MDS [3]. Murine HSCs are
enriched in the bone marrow cell population that do not
express mature hematopoietic cell lineage markers (Lin−),
such as B220, CD4, CD8, Gr-1, Mac-1, and Ter-119, but
do express c-Kit and Sca-1, collectively termed LSK (Lin−-
Sca-1+c-Kit+) cells [26]. HSC and early progenitors can be
Fig. 1 Conditional macroH2A1.1 knockout (KO) in mice. a Upper panel. Targeting construct containing the sequence encoding mouse
macroH2A1 (H2AFY), a loxP-flanked neomycin (neo) cassette 3′ of exon 6b (included in macroH2A1.2), and a rox-flanked cassette 3′ of exon 6a
(included in macroH2A1.1). Lower panel. Targeting construct upon Cre-mediated excision. b Left: phase-contrast of first passage mouse
embryonic fibroblasts (MEFs) after 3 days in culture. Right: protein lysates from MEFs of macroH2A1.1fl/fl and macroH2A1.1−/− (KO) mice were
immunoblotted with anti-macroH2A1.1 and macroH2A1.2 antibodies. Histone H2A was used as a loading control. c macroH2A1.1 and
macroH2A1.2 mRNA levels in adult mice tissues. RNA was extracted from the lung, liver, kidney, seminal gland, intestine, testis, brain, skeletal
muscle, heart, and spleen of 3-month-old macroH2A1.1fl/fl, macroH2A1.1fl/− (HET), and macroH2A1.1−/− (KO) mice, and analyzed by qRT-PCR using
isoform-specific primers. N = 5 mice/group. **p < 0.01; ***p < 0.001 relative to macroH2A1.1fl/fl
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further characterized within the LSK population based on
the surface expression of SLAM (signaling lymphocyte ac-
tivation molecule) markers CD150 and CD48 [27]. Given
the enhanced susceptibility of macroH2A1.1 KO mice to ra-
diation-induced death and cell damage, we tested the effects
of haploinsufficiency and absence of the macroH2A1.1 on
the hematopoietic compartment at a steady state and under
DNA damaging conditions. At a steady state, total bone
marrow cellularity (Fig. 2a) as well as the frequency of the
LSK CD48−CD150+ HSC did not vary significantly among
macroH2A1.1fl/fl, HET and KO mice (Fig. 2b). Because
macroH2A1 isoforms regulate self-renewal and differenti-
ation of induced pluripotent stem cells, embryonic stem
cells and cancer stem cells [11, 16, 28], we hypothesized that
macroH2A1.1 might be involved in regulating the
hematopoietic compartment following genotoxic insult in a
dose-dependent and time-dependent manner. We analyzed
HSCs in the BM of all three macroH2A1.1 genotypes at 1
day (early time point) and 7 days (late time point) after sys-
temic exposure to 600 (low dose) or 1200 rad (high dose) ir-
radiation. Downregulation of c-Kit cell surface expression
on functional HSCs has been reported in the situation of
distress, such as 5-FU treatment and Myc gene deletion
[29]. Since all Lin−Sca-1+CD150+ cells in control animals
are c-Kit+, the Lin−Sca-1+CD150+CD48− marker combin-
ation can also be used to identify HSCs [29]. Since in
irradiated mice, we also observed a dramatic reduction in
c-Kit+ cells (data not shown), we used the Lin−Sca-
Fig. 2 Assessment of the long-term hematopoietic stem-cell (LT-HSC) pool at a steady state and upon irradiation in macroH2A1.1fl/− (HET) and
macroH2A1.1−/− (KO) mice. Live, Lin− cells were gated and analyzed for c-Kit and Sca-1 surface marker expression. Lin−c-Kit+Sca-1+ (LSK) cells
were gated and further analyzed for CD150+ CD48− surface marker expression. Evaluation of the absolute cell number (a) and frequencies
(percentage relative to whole bone marrow cell count) (b) of LT-HSCs in the bone marrow (BM) of macroH2A1.1fl/fl, macroH2A1.1fl/− (HET), and
macroH2A1.1−/− (KO) mice, at a steady state. N = 5–6 mice per genotype. c, d Evaluation of the absolute cell number and frequencies of LT-HSCs
in the BM of irradiated [(600 rad (low dose, c) or 1200 rad (high dose, d)] macroH2A1.1fl/fl, macroH2A1.1fl/− (HET), and macroH2A1.1−/− (KO) mice.
Analyses were performed on days 1 (early time point) or 7 (late time point) after irradiation. Error bars represent the SD. N = 3–4 mice per
genotype. *p < 0.05, **p < 0.01 relative to macroH2A1.1fl/fl
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1+CD150+CD48− marker combination to identify HSC in
WT, HET, and KO mice following different doses of ir-
radiation in comparison to the same population in un-
treated mice. We observed that the macroH2A1.1
haploinsufficiency caused a significant increase in HSC
frequency at late time point following low-dose (Fig. 2c)
and high-dose (Fig. 2d) irradiation compared to WT mice.
Conversely, the macroH2A1.1−/− mice showed a decrease
in HSC frequency, caused by low (Fig. 2c, early time point)
and high (Fig. 2d) doses of irradiation, compared to un-
treated and similarly treated WT mice. Altogether, these
data demonstrate that the macroH2A1.1 isoform regulates
HSC response to irradiation in a time- and dose-
dependent manner.
MacroH2A1.1 haploinsufficiency or deficiency in HSCs
leads to a myeloid differentiation bias in transplantation
assays
A myeloid differentiation bias is found in human patients
with MDS [3]. To understand the downstream effects of
macroH2A1.1 haploinsufficiency or deficiency on HSC/
hematopoietic progenitor cells (HPC) populations, we ana-
lyzed the BM from macroH2A1.1fl/fl, macroH2A1.1fl/−
HET, and macroH2A1.1−/− KO mice by flow cytometry.
Higher frequencies of myeloid (Mac-1+) cells were found in
macroH2A1.1−/− KO mice compared to macroH2A1.1fl/fl
mice, and lower frequencies of B (B220+) cells were found
in both macroH2A1.1fl/− HET and in macroH2A1.1fl/fl mice
(Fig. 3a). To demonstrate that the cause of this myeloid bias
observed in macroH2A1.1−/− KO mice is intrinsic to the
hematopoietic system, we performed an in vivo transplant-
ation study. Here, flow cytometry analysis confirmed higher
frequencies of myeloid cells and lower frequencies of B cells
in the peripheral blood of mice receiving macroH2A1.1fl/−
HET or macroH2A1.1−/− KO BM cells, compared to mice
receiving macroH2A1.1fl/fl BM cells (Fig. 3b–d). The mye-
loid differentiation bias was also observed in HET mice in
noncompetitive BM transplantation assay (Fig. 3c). More-
over, the analysis of the frequencies of myeloid progenitor
sub-populations revealed a tendency increase in GMPs
(Lin/IL7R/Sca-1−c-Kit+CD34+CD16/32+) and a tendency
decrease in megakaryocyte-erythrocyte progenitors (MEPs;
Lin−/IL7R/Sca-1−c-Kit+CD34−CD16/32−) in the BM of
macroH2A1.1fl/− HET and macroH2A1.1−/− KO mice com-
pared to macroH2A1.1fl/fl mice (Fig. 3e). These data show
that decreased macroH2A1.1 levels has a profound impact
on HSC differentiation in the BM, resulting in a myeloid
skewing similar to that observed in human MDS.
Downregulation of ribosomal protein genes after
macroH2A1.1 depletion
To gain a mechanistic insight into the hematopoietic de-
rangements associated with decreased macroH2A1.1 expres-
sion, we performed transcriptome-wide RNA sequencing
(RNA-Seq) to identify differentially expressed genes (DEGs)
between HPCs (CD150−CD48+ LSK) isolated by cell sorting
from macroH2A1.1−/− KO and macroH2A1.1fl/fl mice.
Using a 1.5-fold change threshold, we identified 599 DEGs,
of which 225 were upregulated and 374 were downregulated
in macroH2A1.1−/− compared to macroH2A1.1fl/fl controls
(Additional file 2: Table S1). KEGG analysis revealed that
these genes significantly over-represented the ribosome
pathway, protein processing in the endoplasmic reticulum,
and the cysteine/methionine metabolism pathways (Fig. 4a).
The ribosome pathway was the most significantly enriched
pathway in our experiment (Fig. 4b), with 16 differentially
expressed ribosomal proteins with their functional location
within the large (Rpl) and small (Rps) subunits. Further-
more, we found the broad functions of chromatin modifica-
tion/remodeling, transcription, redox cell metabolism,
cytoskeleton homeostasis, and cellular response to DNA
damage stimulus among the top 20 most represented bio-
logical processes (Gene Ontology, GO) in macroH2A1.1−/−
HPCs (Fig. 4c). As defective ribosome biogenesis has been
reported in MDS [30], we next asked whether
macroH2A1.1-deficiency-driven changes in ribosomal pro-
tein gene expression underpin pathology in hematopoietic
cells. We stably knocked down (KD) macroH2A1.1 mRNA
in human promyelocytic leukemia HL-60 and monocytic
THP-1 cell lines grown in suspension [31], using lentivi-
rally transduced shRNAs against the H2AFY gene. Upon
efficient specific silencing of the macroH2A1.1 transcript
(without altering the levels of macroH2A1.2 isoform)
(Additional file 1: Figure S3A, B), we measured transcript
levels for a subset of Rpl (19, 29, 38) and Rps (15a, 21)
genes, whose expression displayed > twofold change in our
RNA-Seq analysis (Additional file 2: Table S1).
MacroH2A1.1 KD led to decreased Rpl19 (fivefold), Rpl29
(twofold), Rpl38 (fivefold), Rps15a (sixfold), and Rps21
(twofold) mRNA levels in both HL-60 and THP-1 cells
(Additional file 1: Figure S3C, D), consistent with our
RNA-Seq findings made in macroH2A1.1−/− mouse HPCs
(Fig. 4). In order to obtain evidence that macroH2A1.1 de-
ficiency-dependent decreased ribosomal protein gene ex-
pression may lead to defective ribosome biogenesis and
protein synthesis, we assessed the steady-state 47S pre-
rRNA level in macroH2A1.1−/− HPCs, and in human HL-
60 and THP-1 cells KD for macroH2A1.1. Under these
conditions, a ~ 85% decrease in the relative amount of 47S
pre-rRNA was observed in macroH2A1.1−/− HPCs
compared to macroH2A1.1fl/fl HPCs (Fig. 5a). Similarly, a
~ 70% and ~ 60% decrease in the relative amount of 47S
pre-rRNA was observed in HL-1 and in THP-1 cells, re-
spectively (Fig. 5b). In addition, we performed a protein
synthesis inhibition assay using puromycin, an antibiotic
that competes by acting as an analog of the three-terminal
end of aminoacyl-tRNA, disrupting protein synthesis. To
this purpose, we performed a [3H]-leucine incorporation
Bereshchenko et al. Clinical Epigenetics          (2019) 11:121 Page 5 of 14
Fig. 3 MacroH2A1.1 deficiency causes myeloid bias upon bone marrow (BM) transplantation. a Peripheral blood (PB) analysis from
macroH2A1.1fl/fl, macroH2A1.1fl/− (HET), and macroH2A1.1−/− (KO) mice showing the percentage of myeloid-cell (Mac-1+) and B-cell (B220+) gated
populations. b, c Dot plots of PB analysis from animals transplanted with macroH2A1.1fl/fl, macroH2A1.1fl/− (HET), and macroH2A1.1−/− (KO) BM
cells in a competitive (b) or noncompetitive (c) transplantation assay. Both plots show the percentage of myeloid cells (Mac-1+) within engrafted
CD45.2+ cells. d Representative plots indicating in each quadrant the frequency of gated cell populations within CD45.2+ cells. Graphs show the
frequency of [Mac-1+, B (B220+), and T (CD4+/CD8+) cells] within CD45.2+ cells. e Frequencies of CMPs, MEPs, and GMPs in the BM of irradiated
macroH2A1.1fl/fl, macroH2A1.1fl/− (HET), and macroH2A1.1−/− (KO) mice. Graphs represent CMP (Lin−c-Kit+Sca-1−CD34+CD16/32), MEP (Lin−c-
Kit+Sca-1−CD34−CD16/32−), and GMP (Lin−c-Kit+Sca-1−CD34+CD16/32+) frequencies in the BM. Results are presented as the means ± SEM of three
independent experiments. N = 6–10/group. *p < 0.05, ***p < 0.001, NS = not significant
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assay upon treatment with puromycin (0, 0.5, 2 μg/ml) for
72 h in HL-60 and THP-1 cells; our findings show that
protein synthesis was significantly inhibited in HL-1 and
THP1 cells even in the absence of puromycin, and it was
further inhibited upon treatment with 0.5 μg/ml puro-
mycin (Fig. 5c). Two micrograms per milliliter puromycin
was lethal in both cell lines (Fig. 5c).
In fact, macroH2A1.1 KD was associated with a ~ 60–
80% decrease in cell viability of both HL-60 and THP-1
cells (Fig. 6a, b). This decrease was due to increased
apoptosis, as a 48-h pre-incubation of the cells with the
pan-caspase inhibitor Z-VAD-FMK (carbobenzoxy-valyl-
alanyl-aspartyl-[O-methyl]-fluoromethylketone; 10 μM)
completely rescued viability (Fig. 6a, b). Conversely, stable
lentivirus-mediated overexpression of macroH2A1.1 fused
to GFP(9) in HL-60 cells (Fig. 7a) led to increased cell pro-
liferation (Fig. 7b). Treating HL-60 cells with phorbol 12-
myristate 13-acetate (PMA) drives their differentiation
Fig. 4 RNA-Seq and bio-informatic analyses on multipotent progenitor cells (CD150−CD48+ LSK) isolated from bone marrow and using flow
cytometry. a KEGG pathways significantly represented by the differentially expressed genes. Enrichment-log (p values) is reported on the x-axis.
The dashed red line marks the significant enrichment threshold (p value = 0.05). b Mouse KEGG map (mmu03010) of the Ribosome pathway. c
Top 20 most enriched Gene Ontology biological processes. The blue line marks the significance enrichment threshold (p value = 0.05), and text
within a bar refers to the number of significantly expressed genes belonging to a process and the overall enrichment score (into brackets)
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toward a monocytic lineage [32]; however, here, we found
that this process was apparently unaffected by macroH2A1.1
overexpression, with over-expressing cells successfully up-
regulating CD11b expression (Fig. 7c) and becoming adher-
ent (Fig. 7d, e). PMA-driven differentiation was also
unaffected by KD of macroH2A1.1 in the population of cells
that remained viable (Fig. 7e).
MacroH2A1 isoforms’ transcript levels are decreased in
the BM of MDS patients carrying a 5q deletion or U2AF1
S34F mutation
We first compared the BM expression levels of
macroH2A1.1 or macroH2A1.2 between sub-groups of
MDS patients with different genetic abnormalities and
healthy controls (n = 5). MDS patients (n = 24 total)
were categorized as either having a normal karyotype
(NK; n = 4); a 5q deletion (del(5q); n = 15), of which
seven also additional cytogenetic changes; or a non-
del5q abnormal karyotype (AK; n = 5) (Additional file 3:
Table S2). As expected, del(5q) patients expressed signifi-
cantly lower macroH2A1.1 and macroH2A1.2 mRNA levels
compared to healthy controls (p < 0.05), due to the loss of
H2AFY located at 5q31.1 within the commonly-deleted 5q
region (Fig. 8a, b). By contrast, NK and AK MDS patients
showed normal macroH2A1.1/macroH2A1.2 mRNA levels
(Fig. 8a, b). Aberrant H2AFY splicing causing specifically re-
duced macroH2A1.1, but not macroH2A1.2, expression
has been associated with the U2AF1 S34F mutation in
MDS [6]. However, only three MDS patients in this cohort
carried this mutation, and they were not del(5q) carriers
Fig. 5 MacroH2A1.1 deficiency decreases rRNA transcription and protein translation in mouse HPCs (a) and in human HL-60 and THP-1 cells (b),
respectively. a, b Total RNA was extracted and 47S pre-rRNA levels were measured by qPCR in macroH2A1.1fl/fl versus macroH2A1.1−/− HPCs and
in HL-60 or THP-1 control (CTL) cells compared to KD cells for macroH2A1.1, respectively. Data were normalized to the amount of GAPDH mRNA
and to the amount of 47S pre-rRNA in macroH2A1.1fl/fl or in CTL cells, respectively. c Global protein synthesis in HL-60 and THP-1 cells treated for
72 h with puromycin (0, 0.5, 2 μγ/ml) was measured by [3H]-leucine incorporation assay and shown as a percentage of inhibition of control in
CTL and macroH2A1.1 KD HL-60 and THP-1 cells. n = 3. ***p < 0.001 relative to the respective CTL (0 μg/ml puromycin); #p < 0.05, ###p < 0.001
relative to the respective 0.5 μg/ml puromycin condition
Fig. 6 a, b MacroH2A1.1 knockdown (KD) affects cell viability in HL-60 and THP-1 cells. a, b Cell viability assay in HL-60 (a) and THP-1 (b) cells,
incubated or not for 48 h in the presence of 10 μM pan caspase inhibitor Z-VAD-FMK. Data are presented as means relative to CTL cells, +/− SD,
n = 4. ***p < 0.001 relative to CTL
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(Additional file 3: Table S2). When comparing these
U2AF1 mutants versus healthy subjects, we detected a de-
creased, albeit not significant, macroH2A1.1 but not
macroH2A1.2 mRNA expression (Fig. 8c, d), according to
previous studies [6]. These data provide evidence that
macroH2A1.1 mRNA tends to decrease in the BM of MDS
patients carrying the U2AF1 S34F mutation and that both
macroH2A1.1 isoforms’ transcript levels are decreased in
the BM of MDS patients who are del(5q) carriers.
Conclusions
Here, we show that the histone variant macroH2A1.1,
which is downregulated in a subset of patients with
MDS, profoundly affects the survival and differentiation
of murine HSCs/HPCs in vivo and human leukemic cell
lines in vitro. We provide evidence that macroH2A1.1 is
required for normal ribosomal protein gene expression
in HPCs. Without proper expression of this histone vari-
ant, abundant cell death occurred in the hematopoietic
cells. Uncovering the relationship between macroH2A1.1
depletion and defective ribosomal biogenesis in HSCs/
HPCs provides a critical link between this epigenetic
regulator and the molecular pathologies typical of MDS.
Our findings are in line with a recent report from Yip
et al. [6]. These authors analyzed the role of the muta-
tion S34F in the splicing factor U2AF1, which is fre-
quent in MDS: U2AF1 S34F altered mRNA splicing of
many transcripts and among those H2AFY (coding for
macroH2A1.1 and macroH2A1.2). Only 3 out of 29 pa-
tients in our cohort displayed U2AF1 S34F mutation; in
those individuals, we observed a not statistically signifi-
cant tendency toward a decrease in macroH2A1.1, but
not macroH2A1.2 mRNA level: analyses on larger co-
horts are required to corroborate these data [6].
H2AFY is physically localized on the long arm of
chromosome 5, implying a connection with the most
common karyotypic abnormality in MDS—del(5q). As
expected, both macroH2A1.1 and macroH2A1.2 mRNA
levels were found decreased in the BM of del(5q) MDS
patients, compared to healthy subjects.
MacroH2A1.1 but not macroH2A1.2, which is deficient in
poly-ADP-ribose binding, is required for PARP-1 activation
[16, 28, 33, 34]. MacroH2A1 and PARP1 activities have been
Fig. 7 Effect of macroH2A1.1-GFP transgene overexpression, or macroH2A1.1 KD, on cell proliferation and differentiation. a Histones were
extracted from HL-60 cells stably overexpressing a GFP vector or a stable macroH2A1-GFP transgene [9], and lysates were processed for
immunoblotting with an anti-GFP antibody. Representative images are shown. b Cell proliferation assay in HL-60 cells, overexpressing GFP or
macroH2A1.1-GFP, using labeling with carboxyfluorescein diacetate succinimidyl ester (CFSE) dye dilution by flow cytometry, 4 days upon adding
the dye. Data are presented as the percentage of GFP cells, +/− SD, n = 4. **p < 0.01 relative to GFP. c FACS staining for pan-macrophage marker
CD11b in HL-60 cells, overexpressing GFP or macroH2A1.1-GFP, upon treatment with Phorbol 12-myristate 13-acetate (PMA, 25 nM) or an equal
amount of vehicle (DMSO) for 24 h. Representative gating is shown. d Representative images of HL-60 cells in suspension or adherent upon
addition of PMA or DMSO as in c. e Adherent HL-60 cells, overexpressing GFP or macroH2A1.1-GFP, or KD for macroH2A1.1, upon treatment with
PMA or DMSO as in c, were counted. Data are presented as the percentage of total cells (in suspension + adherent). Data are presented as
means +/− SD, n = 4
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independently implicated in ribosome assembly [35–37].
Mutational [38] and transcriptomic [39] approaches have
not fully clarified yet the role of del(5q) in MDS pathogen-
esis; however, CSNK1A1 [40] and RPS14 [41] have been
identified as strong promising therapeutic targets.
Hematopoietic differences observed in macroH2A1.1 hap-
loinsufficient and macroH2A1.1-deleted mice have been
similarly reported in a murine model displaying conditional
inactivation of CSNK1A1 [40]. In this model, CSNK1A1
haploinsufficiency induced HSC expansion, whereas homo-
zygous deletion caused HSC failure [40]. If CSNK1A1 and
macroH2A1.1 functionally interact in regulating,
hematopoiesis remains to be established. The phenotype of
our newly generated macroH2A1.1 haploinsufficient mouse
recapitulates several features of human MDS, including
anemia, neutropenia, expansion of the LT-HSC pool, and a
marked level of susceptibility to irradiation and defective
myelopoiesis [3].
Various transcriptional and epigenetic mechanisms con-
tribute to HSC maintenance and stepwise differentiation to
produce distinct hematopoietic lineages [42, 43], and
macroH2A1.1 has only recently emerged as a novel
epigenetic regulator of hematopoiesis. Silencing
macroH2A1.1 expression in human progenitor cells alters
erythroid and granulomonocytic differentiation, and the re-
introduction of macroH2A1.1 in U2AF1 mutant BM cells
rescues cell death and their differentiation potential [6].
Consistently, we found that in lineage-committed HL-60
(neutrophils) and THP-1 (monocytes) human myelomono-
cytic leukemia cell lines, KD for macroH2A1.1 led to
massive reduction in proliferation and death, and that
macroH2A1.1 haploinsufficiency, and to a lesser extent, its
full deficiency, tends to decrease the frequency of CMPs and
MEPs, and to increase GMPs in mice. Expanded GMPs
characterize high-risk MDS [44]. Compared to in vitro
shRNA-mediated silencing or full in vivo KO, we believe
that the features of our newly generated macroH2A1.1 hap-
loinsufficient mouse might be more akin to the pathological
changes observed in MDS patients. In fact, we also detected
a myeloid bias in mice that lack the full dose of
macroH2A1.1: the hematopoietic cell-autonomous enrich-
ment of myeloid Mac-1+ cells parallels the myeloid differen-
tiation bias that is commonly observed in other MDS
murine models and in human MDS. MDS is characterized
A B
C D
Fig. 8 Expression analysis of two macroH2A1 transcript variants in MDS cells. a, b Relative mRNA expression of macroH2A1.1 (a) or macroH2A1.2
(b) in bone marrow samples from healthy individuals (n = 5), MDS patients with a 5q deletion (del5q; n = 15), or without del5q (NK, normal
karyotype; n = 4), and MDS patients carrying other different chromosomal aberrations (AK, abnormal karyotype; n = 5). c, d MacroH2A1.1 and
macroH2A1.2 mRNA levels were also compared between healthy individuals, MDS patients without the U2AF1 S34F mutation (wild type, wt), and
MDS patients with the U2AF1 S34F mutation (mut). The p values are indicated, compared to healthy individuals
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on one hand by dysplastic myeloid expansion, with myeloid
cells that have reduced ability to differentiate, and on the
other hand by neutropenia, thrombocytopenia, and anemia
[45–47]: we propose macroH2A1.1−/− mouse as a useful
tool for further mechanistic studies on MDS.
By characterizing the phenotype of macroH2A1.1-insuf-
ficient mice, we report also another primary in vivo role
for macroH2A1.1 in hematopoiesis: our RNA-Seq analysis
of HPCs from macroH2A1.1−/− mice identified a substan-
tial depletion of many transcripts [small ribosomal pro-
teins (Rps) and large ribosomal proteins (Rpl)] involved in
ribosome assembly, and this was confirmed in HL-60 and
THP-1 myeloid cell lines. Moreover, we found that
macroH2A1.1−/− HPCs and HL-60/THP-1 KD for
macroH2A1.1 display decreased levels of 47S pre-rRNA, a
long primary transcript that is the precursor of three of
the four ribosomal RNAs: 18S, 5.8S, and 28S. Within ribo-
some structure, the 18S rRNA assembles with 33 Rps to
form the 40S ribosomal subunit or small subunit, while
the 5S, 5.8S, and 28S rRNAs associate with 47 Rpl to as-
semble the 60S or large subunit. 47S pre-rRNA and Rps/
Rpl levels might thus be connected events leading to de-
fective ribosome biogenesis in macroH2A1.1−/− HPCs. Al-
though the causal role for ribosomal biogenesis in HSC
maintenance is not fully understood, impaired ribosome
biogenesis-induced nuclear stress, for instance, due to
hemizygosity for genes encoding ribosomal proteins, is
associated with the development of clinical entities col-
lectively known as “ribosomopathies” which include sev-
eral bone marrow failure syndromes, including MDS [48].
We speculate that macroH2A1.1 depletion in the
hematopoietic system might have two deleterious effects.
First, it alters HSC homeostasis through defective riboso-
mal production [30]: adult HSCs display low levels of glo-
bal protein synthesis relative to HPCs and genetic
perturbations that alter the dynamics of protein synthesis
impair HSC function [49]. Our data suggesting that
macroH2A1.1-dependent impairment in ribosome bio-
genesis relates to impaired HSC differentiation are con-
sistent with Signer et al., who demonstrated that reduced
ribosome function in Rpl24 mice reduced protein synthe-
sis of 30% in HSCs and impaired HSC function [50].
Second, given the extensive Rpl and Rps expression
heterogeneity in the hematopoietic system [51],
macroH2A1.1−/− might disrupt the regulation of
hematopoietic lineage-specific ribosomal proteins that
might be involved in lineage differentiation. Predicting
the phenotypes of perturbed Rpl and Rps expression pat-
terns remains challenging and is an area that warrants
future research.
In summary, our study shows that a loss of
macroH2A1.1, which affects a subset of MDS patients, has
a critical role in the defective hematopoiesis and perturbed
ribosomal biogenesis that are central to MDS pathology.
By combining clinical data with a discrete mutant mouse
model and in vitro studies of human cells, we identify
macroH2A1.1 as a key determinant of the cellular and
molecular features of MDS. These data justify the explor-
ation of macroH2A1.1 and associated proteins as thera-
peutic targets in hematological malignancies.
Methods
Clinical and laboratory data of MDS patients
Bone marrow aspirates, clinical information, and routine
laboratory data were collected from 24 patients diag-
nosed with MDS according to the revised World Health
Organization criteria [52] and prior to commencement
of treatment, at the University Hospital Brno. Basic
MDS patients and cytogenetic characteristics are shown
in Additional file 3: Table S2. U2AF1 mutation analyses
were performed as described previously [6].
Human bone marrow cell isolation and sample processing
Red blood cells were depleted using ACK lysing buffer
(NH4Cl 150 mM, KHCO3, 10 mM, Na2EDTA 0.1 mM,
pH 7.2). White blood cells were further processed for
RNA isolation. Total RNA was isolated using TriReagent
(MRC, USA) according to the manufacturer’s instruc-
tions and the quality of RNA was assayed with an Agi-
lent 2100 Bioanalyser (RNA 6000 Nano Assay; Agilent
Technologies, USA).
Animal models
Mice lacking macroH2A1.1 were generated as follows: a
12 kb segment of the murine H2AFY gene (introns 5–8)
was subcloned from a BAC by recombineering into
p15A-HSV tk-DTA-amp. A lacZ-neo cassette [53],
flanked by loxP and rox sites at the 5′ and 3′ ends, re-
spectively, was inserted into the intron between exons 6a
and 6b, also by recombineering [54]. Another rox site
was inserted upstream of exon 6a and another loxP site
inserted downstream of exon 6b so that Dre/rox recom-
bination [55] would remove exon 6a and the lacZ-neo
cassette, and Cre/loxP recombination would remove
exon 6b and the lacZ-neo cassette; thus, Cre recombin-
ation will eliminate macroH2A1.1 expression. Southern
blotting of genomic NheI-digested DNA from individual
ES-cell-derived clones with a 3′ probe was used to identify
homologous recombinants (Additional file 1: Figure S1). A
12.3-kb DNA fragment corresponds to the wild-type
macroH2A1.1 locus; integration of the loxP-flanked neo-
mycin cassette 3′ of exon 6b introduced an additional
NheI site, thus increasing the size of the NheI DNA frag-
ment to 16.2 kb in the targeted allele (Additional file 1:
Figure S1). Cre-mediated recombination resulted in a 3.9-
kb NheI DNA fragment recognized by the 3′ probe, which
is diagnostic of the macroH2A1.1 allele. The targeting of
the macroH2A1.1 allele was performed by electroporation
Bereshchenko et al. Clinical Epigenetics          (2019) 11:121 Page 11 of 14
of A9 ES cells, which were then injected into C57BL/6
eight cell-stage embryos. The targeted macroH2A1fl/fl
mice were crossed to deleter HPRT-Cre mice (129S1/Sv-
Hprttm1(CAG-cre)Mnn/J), purchased from Jackson Laborator-
ies, USA, to remove the loxP-flanked neomycin cassette
and generate macroH2A1.1fl/− mice (heterozygous, HET),
respectively. Mice heterozygous for the macroH2A1.1 al-
lele were further crossed to deleter Cre mice to generate
the macroH2A1.1−/− (knockout, KO) mice, respectively.
All mice used were obtained after eight generations of
back crossing on a C57Bl/6 genetic background. Mice
were bred and maintained at the EMBL Mouse Biology
Unit, Monterotondo, or at Plaisant Srl (Rome, Italy), in ac-
cordance with current Italian legislation (article 9, 27
January 1992, number 116) under a license from the Ital-
ian Health Ministry. The congenic C57BL/6-Ly5.1 mice
were purchased from Charles River Laboratory. C57BL/6-
Ly5.1/2 recipients were generated by intercrossing
C57BL/6-Ly5.1 and C57Bl/6-Ly5.2 mice (Harlan, Italy).
Bone marrow transplantation assays
Radiation chimeras were generated as described [56]. For
competitive transplantation assays, a 1:3 mixture of BM
cells from the donor macroH2A1.1fl/fl, macroH2A1.1
HET, or macroH2A1.1 KO mice (CD45.2+) and helper
WT (CD45.1+) mice, respectively, was injected into the tail
vein of the recipient (CD45.1/2+) mice. For noncompeti-
tive transplantation assays, 1 × 106 BM cells from macro-
H2A1.1fl/fl, macroH2A1.1 HET, or macroH2A1.1 KO
mice (CD45.2+) were injected into the recipient mice. The
recipient mice were treated with Baytril (Enrofloxacin,
Bayer) in drinking water (17mg/ml) for the duration of
the experiment.
Statistical analyses
Data are shown as means ± standard error of the mean
(SEM). Groups were compared with either Student’s t
test or the non-parametric Mann-Whitney U test, as ap-
propriate, using GraphPad Prism Software (version 5.00
for Windows, San Diego, CA, USA): significance was
p ≤ 0.05. Survival analyses of mice employed the Kaplan-
Meier estimator.
Additional files
Additional file 1: Supplemental Material and Methods. Figure S1.
Conditional KO of macroH2A1.1 in mice. A. Upper panel. Targeting
construct containing the sequence encoding mouse macroH2A1
(H2AFY), a loxP-flanked neomycin (neo) cassette 3′ of exon 6b (included
in macroH2A1.2), and a rox-flanked cassette 3’of exon 6a (included in
macroH2A1.1). Lower panel. Target construct upon Cre-mediated
excision. B. Southern Blot strategy to screen for positive clones: genomic
NheI-digested DNA from individual ES-cell-derived clones with a 3′ probe
was used to identify homologous recombinants. A 12.3-kb DNA fragment
corresponds to the wild-type macroH2A1.1 locus; integration of the loxP-
flanked neomycin cassette 3′ of exon 6b introduced an additional NheI
site, thus increasing the size of the NheI DNA fragment to 16.2-kb in the
targeted allele. Figure S2. Peripheral blood counts and biochemical
parameters in macroH2A1.1 Fl/- and 1 KO mice. Blood samples were
collected into heparinized containers from wild type (WT), macroH2A1.1
Fl/Fl, macroH2A1.1 Fl/- and KO mice via tail vein. Data are expressed as
mean ± SEM. * p < 0.05; **p < 0.01; ***p < 0.001 as compared to
macroH2A1.1 Fl/Fl. N=12-15 per each group. Figure S3. Effect of
macroH2A1.1 knock/down (KD) on ribosomal protein gene expression in
HL-60 and THP-1 cells. A, B. RNA was extracted from HL-60 (A) or THP-1
(B) cells stably overexpressing a vector carrying scrambled shRNA (CTL) or
a vector carrying shRNA for macroH2A1.1 (KD), and processed for qPCR
using specific primers against macroH2A1.1 or macroH2A1.2 transcripts.
C, D. RNA was extracted from HL-60 (C) or THP-1 (D) cells stably
overexpressing a lentiviral vector carrying scrambled shRNA (CTL) or a
vector carrying shRNA for macroH2A1 (KD), and processed for qPCR
using specific primers against Rpl19, Rpl29, Rpl38, Rps15a and Rps21
transcripts. Data are presented as means relative to CTL cells, +/- SD, n =
4. *** P < 0.001 relative to CTL. (DOCX 680 kb)
Additional file 2: Table S1. Basic MDS patient/sample characteristics.
Patients are classified according to the WHO classification 2016 13. Excel
file provided separately. MDS-SLD - MDS with single lineage dysplasia.
MDS-MLD - MDS with multi-lineage dysplasia. MDS-RS-MLD - MDS with
ring sideroblasts and multi-lineage dysplasia. MDS-EB-1 - MDS with
excess blasts-1. MDS-EB-2 - MDS with excess blasts-2. 5q- syndrome -
MDS with isolated del(5q). (XLSX 56 kb)
Additional file 3: Table S2. List of 599 transcripts displaying >1.5 fold
change in hematopoietic progenitor cells (HPC) isolated from bone
marrow of macroH2A1.1 KO versus Fl/Fl mice. (PDF 295 kb)
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